58 results about "Thymosin" patented technology

Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide.

We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.

The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.

The invention discloses a method to manufacture biology polypeptide, especially a method to make natural human thymosin by gene series express method. It contains compounding two polynucleotide section, compounding double enzyme cut, T alpha 1 gene three times connecting in series, constructing high efficiency expression, constructing engineering fungus, expressing T alpha 1 polypeptide six series bodies in engineering fungus, purifying and cracking. The invention could abundantly express aim albumen, and it has simple technology, easy to operate and low cost.

The invention relates to a porcine circovirus type 2 Cap protein, thymosin alpha1 fusion protein and an application, and an amino acid sequence of the fusion protein is shown as SEQ ID NO:1. The fusion protein can be used for preparing porcine circovirus type 2 subunit vaccine. The screened porcine circovirus type 2 Cap protein and a thymosin alpha1 gene having immunological enhancement effect are connected through a Lingker sequence to obtain the fusion protein. The genetic engineering subunit vaccine of the invention has good immunogenicity, and the immune response of piglet can be caused with high efficiency.

The invention relates to a recombined extrasin alpha 1 two-strand body protein and a preparation method thereof. Glycin and serine are connected in series with bimolecular extrasin alpha 1 (T alpha 1), a connection mode is as follows: T alpha 1-Gly-Ser=T alpha 1, and an extrasin alpha 1 two-strand body gene expression vector is constructed by synthesized extrasin alpha 1 two-strand body genes so that extrasin alpha 1 which can not be directly expressed in colon bacillus can be efficiently expressed in the colon bacillus in a two-strand body way. The purified extrasin alpha 1 two-strand body protein has biological activity and can promote lymphocytes of small mice to proliferate, restrain tumor cell strains from proliferating and obviously restrain the tumor growth of tumor-bearing mice, thereby establishing a base for the further research and the extensive application of the extrasin alpha 1.

The present invention relates to thymosin β-4 peptides and analogs thereof that can promote tissues regeneration, particularly cardiac tissue.

The invention discloses a recombinant thymosin protein PaTHY1 of Periplaneta americana and an expression method thereof, belonging to the field of biotechnology. The expression method comprises the following steps: (1) extracting RNAs from the tissue of Periplaneta americana and carrying out inverse transcription on the RNAs to obtain cDNAs; (2) synthesizing primers; (3) with the cDNAs as a template, carrying out PCR to obtain a coding gene fragment of the thymosin protein of Periplaneta americana; (4) cloning the coding gene fragment into a prokaryotic expression vector for transformation ofhost bacterium, carrying out culturing on an obtained recombinant engineering bacterium and inducing the recombinant engineering bacterium to express the target protein; and (5) purifying the target protein by using affinity chromatography so as to obtain the recombinant thymosin protein PaTHY1 of Periplaneta americana. The recombinant protein is obtained through genetic engineering for the firsttime, overcomes the problems of low content and difficult purification of thymosin in complex chemical components of Periplaneta americana, and lays a foundation for research on the pharmacodynamic functions of thymosin from Periplaneta americana.

The invention discloses a method for purifying thymosin beta4 with a reversed phase high performance liquid chromatography, which is mainly used for solving the technical problem of low purity of thymosin beta4 obtained by separating in the prior art. According to the technical scheme of the invention, the method comprises the following steps of: (1) dissolving a crude peptide obtained by synthesizing solids with deionized water, gradually eluting and purifying by taking a reversed phase silica gel column of which the immobile phase is tetraalkylsilane bonded silica gel or octadecyl bonded silica gel and the mobile phase is a phosphate buffer solution as a phase A and taking chromatographically-pure acetonitrile as a phase B, and collecting a peptide solution of a target peak value; (2) switching and transforming into acetate by using an HPLC (High Performance Liquid Chromatography) method; and (3) and performing spinning evaporation, concentration and freeze drying on a final high-purity peptide solution under reduced pressure to obtain a powdery finished peptide. The invention provides a method for purifying thymosin beta4, which is suitable for industrialization. According to the method, fine peptides of which the purities are over 98.0 percent can be obtained, batch production is available, and the requirements of high purity, high yield, low cost and high efficiency are met.

The invention discloses a grass carp thymosin extrasin beta11 gene sequence. A full expression sequence of a grass carp thymosin extrasin beta11 gene is obtained with a PCR (Polymerase Chain Reaction) method by designing primers with a thymosin extrasin beta11 EST sequence of a grass carp intestinal tract cDNA library preserved in the local laboratory used as a template, and combining with a RACE (Rapid Amplification of cDNA Ends) technology. The invention provides important theoretical basis for researching the structural constitution of the grass carp thymosin extrasin beta11 gene, and probing into the function of the grass carp thymosin extrasin beta11 gene in the disease resistant mechanism of grass carps, the position of the grass carp thymosin extrasin beta11 gene in a functional area, and the difference with other species, and plays a pathbreaking role of exploration on establishing a bond between a grass carp genome project and a research on the grass carp disease resistant mechanism.

The invention belongs to the field of pharmacology, discloses an application of thymosin or a derivative thereof and a medicine for treating depression, and particularly discloses an application of the thymosin or the derivative thereof in preparation of the medicine for treating the depression. The invention also discloses a pharmaceutical composition for treating the depression, and the pharmaceutical composition comprises a treatment effective dose of the thymosin or the derivative thereof. In the technical scheme of the invention, the systemic administration of the thymosin or the derivative thereof, especially thymosin [beta]4 or a derivative thereof, is safe, and the thymosin or the derivative thereof has a good curative effect on the depression and is tolerated by animals includinghuman beings.

The invention discloses preparation and application methods of a genetically engineered bacterium expressing thymosin beta4. The preparation method comprises the following steps: S1, synthesizing a gene sequence of the thymosin beta4 which can be efficiently expressed in escherichia coli; S2, recombining the obtained gene into a SapI digested pTWIN1 plasmid vector to obtain a pTWIN-Tbeta4 fusion vector; S3, by taking the pTWIN-Tbeta4 as a template, carrying out PCR (Polymerase Chain Reaction) amplification on a contained peptide sequence and a Tbeta4 sequence on the vector; S4, recombining the obtained gene sequence to NcoI and XhoI digested plasmid pET-28a to obtain a pET-Tbeta4 expression vector; S5, converting the obtained vector to a competent escherichia coli cell BL21 to obtain a pET-Tbeta4 engineering bacterium; and S6, adding IPTG (Isopropyl-beta-D-Thiogalactoside) to induce Tbeta4 to express when the OD600 value of the obtained bacterial liquid is 0.4-0.6. The invention further discloses an application method of the genetically engineered bacterium expressing the thymosin beta4. The preparation and application methods of the genetically engineered bacterium expressing the thymosin beta4 provided by the invention lay a foundation for environment-friendly production of the thymosin beta4 with a low cost.

The invention discloses a thymosin beta4 gene expression inhibiting RNA and use thereof. The shRNA provided by the invention is a single-chain RNA having a stem-and-loop structure consisting of a stem I, a loop and a stem II; the sequence of the stem I is represented by the sequence 1 in a sequence table; and the sequence of the stem II is represented by the sequence 2 in the sequence table. The RNA of the invention can be used to construct recombinant plasmids and recombinant lentiviruses and obviously inhibit the invasion by tumor cells, the propagation of tumor cells and the expression of the thymosin beta4 gene in cells, thereby having medicinal and pharmaceutical applications and profound significance.

The anti-thymosin pro-alpha polyclonal antibody and its preparation method and application relate to an anti-thymosin pro-alpha polyclonal antibody. The anti-prothymosin α polyclonal antibody is a polyclonal anti-GST-ProTα antiserum obtained after immunizing New Zealand white rabbits with a fusion protein prepared by using GST-ProTα fusion expression. First prepare the fusion protein GST-ProTα, and then prepare the antibody. It can be used for immunoblotting and ELISA immunoassay of various samples and cells containing ProTα components, and tissue endogenous ProTα. Using the antibody to detect the ProTα level in urine can be used to diagnose urinary system tumors such as bladder cancer, kidney cancer and prostate cancer. The antibody has high titer and strong specificity. Various samples containing ProTα can be detected. Using prothymosin α in urine as a tumor marker for the diagnosis of urinary system cancer. The total process does not exceed 4 hours, and the required amount of samples is small.

The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring Tβ4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin β-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth.

The present invention belongs to the field of molecular biology and biological technology. From thymus tissue of milk cow, the milk cow prothoracic gland hormone coding gene is separated. Specific primer pair for inverse transcription and PCR proliferation is designed, and the milk cow prothoracic gland hormone coding gene separated via inverse transcription and PCR has sequence length of 330 bases. The expression vector is further constituted for transforming host cell to obtain prothoracic gland hormone protein with high activity from the host cell culture liquid. The recombinant gene of the present invention may be used in the industrial production of thymosin as one medicine product.

The invention belongs to the technical field of biomedical engineering, and discloses a preparation method of a wound dressing for relieving scar generation, which comprises the following steps: (1) activating illite nano powder; (2) adding TPU particles, the activated illite nano powder, hyaluronic acid, dracorhousin, hirudin and thymosin beta4 into DMF (Dimethyl Formamide), and stirring at 4 DEG C to obtain a core layer spinning solution; (3) taking collagenase and the activated illite nano powder, adding hexafluoroisopropanol, stirring at 4 DEG C overnight, adding collagen and a pseudo-ginseng extract, and stirring at 4 DEG C to obtain a shell spinning solution; (4) preparing nanofibers through coaxial electrospinning; and (5) coating the PVP layer. The prepared wound dressing can stop bleeding and resist bacteria in the early stage of wound healing and remove extravasated blood and resist scars in the later stage of wound healing.

The invention discloses a thymosin beta4 medicinal preparation for treating depression as well as a preparation method and application of the thymosin beta4 medicinal preparation, and belongs to the technical field of disease treatment. The mouse depressive behavior is induced mainly by establishing a chronic social defeat stress model (CSDS), and the model has the advantages that the model simulates social attributes in human chronic stress, and then after nasal administration of T beta 4 is conducted for seven consecutive days, the mouse depressive behavior is induced. Through a social interaction test (SIT), a tail suspension test (TST), a sucrose preference test (SPT) are and other behavioral tests are carried out to evaluate the depression level, and the result shows that T beta4 hasa rapid anti-depression effect in mice, and can reverse CSDS-induced depression-like behaviors within 7 days.

The related fused protein prepared by both of one protein stable expressed in bacterium and the natural thymosin a1 can take large-production soluble expression in colibacillus. It also relates a1 derivant with high biological activity. This invention can be used on assisted cancer cure.

The invention relates to long-acting thymosin alpha1-polyethylene glycol modifiers(T alpha1-PEGs) and a preparation method thereof, a pharmaceutical composition containing the same and applications to treating or preventing diseases related to immunodeficiency, immunologic hypofunction, and the like. The long-acting thymosin alpha1-polyethylene glycol modifiers(T alpha1-PEGs) are applied to treating or preventing diseases related to hepatitis B, hepatitis C, liver cancer, malignant melanoma, non-small cell lung cancer, and SARS, AIDS, and the like which are caused by coronavirus.

A method for using thymosin β-10 for cancer treatment by expressing thymosin β-10 in solid malignant tumor cells. More precisely, the present invention relates to a cancer treatment method wherein thymosin β-10 is expressed in solid malignant tumor cells by infecting adenovirus including thymosin β-10. The gene therapy for cancer using thymosin β-10 of the present invention is very effective for the treatment of ovarian cancer, cervical cancer, stomach cancer and lung cancer.

The invention provides a pharmaceutical composition ethosome, which is prepared from the following components in percentage by weight: 0.1 to 0.2 percent of thymosin beta4, 0.5 to 1 percent of glucocorticoid, 30 to 50 percent of low-molecular-weight alcohol, 3.0 to 12.0 percent of phospholipid, 1.0 to 2.5 percent of cholesterol, 0.51 to 1.3 percent of auxiliaries and the balance of PBS (Phosphate Buffer Solution). The invention also provides a method for preparing the pharmaceutical composition ethosome for treating scars. According to the ethosome, the dosage of hormone can be reduced, side effects can be reduced, the treatment effect is more lasting, scars can be shrunk in the medication process, and after medication is stopped, the scars are not prone to relapse and reach 1 + 1gt; and 2, efficacy. The ethosome disclosed by the invention is strong in transdermal ability, high in encapsulation efficiency, large in drug loading capacity, good in stability and easy to store and use. In addition, the ethosome provided by the invention has toxic and side effects, and is convenient, safe and controllable in administration, good in compliance and higher in bioavailability.

The invention relates to a preparation method of recombination human thymosin beta 16, belonging to the field of biological engineering. The invention aims at adopting a genetic engineering technology to prepare the recombination human thymosin beta 16. The recombination human thymosin beta 16 has an amino acid sequence: SEQ ID NO: 1. The T beta 16 is used as one of thymosin family members, has a wound healing promoting function different from the same-effect medicines applied to a market or in a developing process. The T beta 16 is not a growth factor. Compared with various growth factors, the T beta 16 has multiple advantages for healing wounds.

The invention relates to a preparation method of a thymosin alpha1 pegylation modifier (Talpha1-PEGs), a medicinal composition containing Talpha1-PEGs, and an application of the medicinal composition to treatment or prevention of relevant diseases such as immunodeficiency or immunologic function immunodeficiency and the like, including an application to the treatment or prevention of relevant diseases such as hepatitis B, hepatitis C, liver cancer, malignant melanoma, non-small cell lung cancer, SARS (Severe Acute Respiratory Syndromes) caused by coronaviruses, acquired immunodeficiency syndrome and the like.

The invention discloses a thymosin [alpha]1-porcine interferon [alpha] fusion protein gene and a preparation method of recombinant protein of the fusion protein gene. A nucleotide sequence of the reconstructed thymosin [alpha]1-porcine interferon [alpha] fusion protein gene provided by the invention is shown as SEQ ID NO.1. Meanwhile, the invention discloses a method for preparing the recombinant protein expressed by the gene and for conducting activity detection, wherein specifically, the method comprises such steps as reconstructing the thymosin [alpha]1-porcine interferon [alpha] fusion protein gene, cloning the gene and promoting secretory expression of the gene in pichia pastoris, preparing the recombinant protein and controlling fermentation culture conditions, improving such operating methods as the activity detection method and the like. The method provided by the invention is simple and easy to implement and is relatively low in cost; the efficient and stable secretory expression of the thymosin [alpha]1-porcine interferon [alpha] fusion protein in the pichia pastoris is achieved; and the expressed recombinant fusion protein is high in anti-viral activity and immune cell regulating activity levels; therefore, the invention lays a foundation for preparing green and no-residue biological products having functions of treating porcine viral diseases and immune regulation.

The invention discloses a method for preparing a method for preparing genetic engineering N-acetylated thymosin alpha1. The method comprises the following steps of: 1) preparing precursor proteins or polypeptides containing a polypeptide sequence of the N-acetylated thymosin alpha1 by genetic engineering escherichia coli; and 2) performing restriction enzyme digestion of the precursor proteins or polypeptides containing the polypeptide sequence of the N-acetylated thymosin alpha1, obtained by the step 1, by endopeptidase, and then purifying the products to obtain the N-acetylated thymosin alpha1. The method has the advantages of obtaining an expression level of the N-acetylated thymosin alpha1, simplifying cutting, facilitating the purification of the N-acetylated thymosin alpha1, improving the production efficiency of the N-acetylated thymosin alpha1, having wide clinical application prospect, along with low cost and the like.

The invention provides a method for inducing hematopoietic stem cells to differentiate into regulatory T cells in vitro. The method comprises the following specific steps: 1, collecting blood; 2, separating and sorting the blood to obtain CD34+, CD38+ and CD39+; 3, selecting the remaining cells in the step 2 to prepare DC cells; 4, carrying out first induction on the cells obtained by sorting in the step 2; 5, performing induction for the second time; and 6, carrying out third induction to obtain CD4+, CD25+ and Foxp3+ regulatory T cells. The method has the beneficial effects that CD34+, CD38+ and CD39+ cells are separated from human peripheral blood, thymosin [alpha]1, IL-2, IL-3, IL-15, TGF-[beta], atRA, TRAF6 and irradiated DC cells are added, and finally human hematopoietic stem cells are induced into regulatory T cells with an immunosuppression function.

Application of thymosin extrasin alpha in preparing medicines for preventing and curing cancer of the liver relates to thymosin extrasin alpha, and effect of the thymosin extrasin alpha in restaining regulatory T-lymphocyte cells is further provided. The effect of recombinant proteins in preventing and curing the cancers of the liver is observed by injecting the thymosin extrasin alpha in intraperitoneal mode, and size of the tumor of the liver and ascites forming prevention are included. Through injection treatment and prevention of the thymosin extrasin alpha, growth of the tumor of the liver can be obviously restrained and simultaneously formation of the ascites can be reduced. By observing level of the regulatory T-lymphocyte cells of mouse splenic organs, the level of the regulatory T-lymphocyte cells of splenic organs in a contrast group is proved to be obviously higher than that of regulatory T-lymphocyte cells of normal mouse splenic organs, and difference is remarkable (P<0.01); and the level of the regulatory T-lymphocyte cells of splenic organs in a medicine-used group is obviously lower than that of the normal contrast group and the experiment contrast group, and the difference is obvious (P<0.01).